Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
ABBV • Stock • Health Care / Biotechnology
Current Price
$262.82
+1.11%
Provider quote snapshot • As of 2026-10-02T20:00:00.000Z
Back to stock pageCross-Horizon Read
ABBV's evidence points supportive across the available windows.
Generated 2026-10-05T10:50:00.000Z • Evidence eaf65220
Price Data
A quote snapshot is available, but historical price data is not connected yet.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads bullish.
Supporting articles
6
Opposing articles
1
Neutral articles
8
Confidence basis
Supporting evidence
• If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
• AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026
• Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
• Is AbbVie Stock About To Break Out Again?
• Wolfe Research Upgrades AbbVie (ABBV)
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
Opposing evidence
• AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data
Catalysts
• Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
• Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303
• Wolfe Research Upgrades AbbVie (ABBV)
• Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target
Risks
• AbbVie Still Has Room To Run
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (6) grows relative to opposing evidence (1) in this window.
Weakens if
• Opposing evidence (1) grows relative to supporting evidence (6) in this window.
Showing 8 of 15 sources
AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data
Benzinga • 2026-08-27 • Bearish
Open via Finnhub →If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
Benzinga • 2026-08-26 • Bullish
Open via Finnhub →AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026
Yahoo • 2026-08-21 • Bullish
Open via Finnhub →AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer
Benzinga • 2026-08-21 • Neutral
Open via Finnhub →AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
Yahoo • 2026-08-21 • Neutral
Open via Finnhub →Most Of What Moves AbbVie Stock Has Nothing To Do With The Market
Yahoo • 2026-08-21 • Neutral
Open via Finnhub →Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
Yahoo • 2026-08-20 • Bullish
Open via Finnhub →